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S258 Poster Session Iprednisone. Patients werematched at 4 (9%), 5 (67%) or 6 (24%) of 6
loci (high resolution at DRB1). Incidence of acute GVHD grade II-
IV was 36% and grade III-IV was 21%. Chronic GVHDwas absent
in 88% of evaluable patients, but limited in 12% with none having
extensive cGVHD. Please see Table for survival data.
Conclusion: Cord blood transplant offers a viable alternative to
bone marrow as a source of hematopoietic stem cells for transplan-
tation. Over the 16 years that cord blood has been used at our insti-
tution, significant improvement in survival was appreciated over the
latter half of that period. This is most likely do to a number of factors
including transplant center experience, improvements in supportive
care, more cord units available to select from and better appreciation
of factors (such asminimumnumber of cells needed for engraftment)
important in choosing the optimal graft. These results compare
favorably with matched bone marrow transplant controls.285
DOES EARLY INITIATION OF THERAPEUTIC PLASMA EXCHANGE AFFECT
OUTCOME IN PEDIATRIC STEM CELL TRANSPLANT-ASSOCIATED
THROMBOTIC MICROANGIOPATHY?
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Stem cell transplant (SCT)-associated thrombotic microangiop-
athy (TMA) is a serious complication leading to acute and chronic
kidney injury, often with high mortality. The diagnosis of TMA is
challenging, and its unclear pathogenesis limits development of op-
timal therapies. We retrospectively reviewed 10 patients with TMA
receiving therapeutic plasma exchange (TPE). Criteria for TMA
diagnosis included microangiopathy (anemia, thrombocytopenia,
elevated LDH, decreased haptoglobin, presence of schistocytes, neg-
ative DAT) and impaired renal function.
TMAwas diagnosed within 100 days post-SCT in 9 of 10 patients.
Three of 10 patients had renal biopsy-proven TMA. These biopsies,
even though challenging in SCT, aided in the decision to institute
therapy. Direct sequence analysis of the complement genes CH1,
CFH, MCP, CFB, and CFR5 was performed in 4 patients and was
normal. However, 2 of these 4 patients had detectable CFH autoan-
tibodies. IL-8 and IL-6 levels were elevated in the 4 patients tested
for plasma cytokines. Seven patients were on renal replacement ther-
apy (RRT) and 6 on ventilator support during TMA. Eight patients
received 2-4 weekly rituximab doses without full response and pro-
ceeded to TPE, while 2 started rituximab and TPE concomitantly.
Single volume daily TPE was initiated 4-73 days after TMA diagno-
sis, continued until resolution of microangiopathic anemia, and then
tapered off after a median of 35 TPE sessions (range 17-79).
Even though 9/10 patients showed laboratory resolution of micro-
angiopathic anemia duringTPE, only 5 patients survived at amedian
of 525 days post-SCT (range 217-777 days). The 5 survivors started
TPE a median of 17 days (range 4-25 days) after TMA diagnosis,
while the 5 patients who died startedTPE amedian of 32 days (range
17-73 days) after TMA diagnosis. Notably, 3 of the 5 survivors had
multiorgan failure at TMA diagnosis and completely recovered
with early institution of TPE. All survivors eventually had normal
creatinine off RRT. Conversely, the 5 patients who had late institu-
tion of TPE developed chronic renal dysfunction (n 5 1) or end-
stage renal disease (n 5 4) and died at a median of 334 days post
SCT (range 151-631 days). Our data suggest the survival benefit of
early TMA diagnosis and therapy with TPE and rituximab which
may work by removing CFH autoantibodies or endothelium damag-
ing cytokines. Larger, prospective studies are required to evaluate
the benefit of these therapies in TMA.286
IV BUSULFAN ADMINISTERED q12 VS q6 HRS DURING CONDITIONING
OF PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (AlloSCT)
RECIPIENTS HAS COMPARABLE PHARMACOKINETICS AND SIGNIFICANT
REDUCTION IN NURSING/PHARMACIST COSTS
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Inaccurate busulfan dosing during AlloSCT conditioning can re-
sult in graft failure or regimen-related toxicity (Andersson, BBMT,
2009). IV busulfan divided q6hrs is safe and effective in pediatric Al-
loSCT recipients at a dose of 4 mg/kg/day in patients# 4 yrs old and
at a dose of 3.2 mg/kg/day in patients . 4 yrs old (Wall et al, PBC,
2010). Less frequent dosing regimens are attractive for the possibility
of cost-effectiveness, but data is limited on comparing q12 to q6hr
infusions of IV busulfan in pediatric AlloSCT recipients.
We compared two cohorts of pediatric AlloSCT recipients receiv-
ing IV busulfan during conditioning. Cohort A received IV busulfan
q6hr x 16 doses and cohort B received IV busulfan q12hr x 8 doses
(age # 4yrs received 4.0 mg/kg/day; age . 4yrs received 3.2 mg/
kg/day). Busulfan levels were obtained at 1, 2, 3, 5, 6 and 8 hours after
the first dose and measured by gas chromatography – mass spectros-
copy (GC-MS) of heparinized plasma. The area under the curve
(AUC) was calculated by a 1-compartment modeling system. Pa-
tients in cohort B were monitored throughout AlloSCT for develop-
ment of moderate to severe hepatic veno-occlusive disease after
administration of IV busulfan. Finally, the savings of the q12 vs
q6hr dosing interval were estimated based on pharmacist/nurse sal-
ary and difference in the frequency of IV busulfan administration be-
tween the two cohorts.
In comparing cohort A (q6hr; n5 89; mean age 7.9 yrs) vs cohort
B (q12hr; n 5 38; mean age 8.7 yrs) there was no statistically signif-
icant difference in the volume of distribution (Vd(L)), half-life (min),
or clearance (Cl (ml/min/kg)).
Cohort A Cohort B
Q6 IV Bu Q12 IV Bu P valuesN 89 38 N/A
Age (yrs) 7.9 ± 6.9 8.7 ± 7.6 0.586
Weight (kg) 30.91 ± 24.6 28.2 ± 19 0.509
Vd (L) 20.6 ± 16.6 19.4 ± 13.7 0.676
Half-life (min) 132.0 ± 31.1 129.10 ± 38.15 0.678
Cl (ml/min/kg) 3.6 ± 0.9 4.0 ± 1.5 0.215
AUC (mmol *min/L) 1077 ± 352 1886 ± 420 <0.0001
Salary Cost ($USD/pt) $3,413 $1,733 N/AAs expected, there was a significant increase in the AUC in cohort B
(q12hr) vs cohort A (q6hr) (18866420 vs 10776352 mmol*min/L; p
\0.0001). Within cohort B (q12hr) there was only a 1/38 incidence
of moderate to severe VOD. Based on bedside RN salary of $40/hr
and pharmacist salary of $60/hr, a cost savings of $1,680/patient
was estimated with q12 vs q6hr IV busulfan dosing.
In summary, IV busulfan q12 vs q6hr dosing during conditioning
of pediatric AlloSCT recipients results in comparable busulfan Vd,
half-life, and Cl and, as expected, a significant increase in AUC. Fur-
thermore, IV q12hr busulfan results in a very low incidence of VOD
in pediatric AlloSCT recipients. Finally, a significant cost reduction
with decreased nursing and pharmacist costs can be achieved with
q12hr administration of IV busulfan.287
UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR
CHILDREN WITH b-THALASSEMIA MAJOR
Shah, S.A., Beniwal, S.K., Shah, K.M., Patel, K.A., Patel, K.M.,
Shah, P.M. Gujarat Cancer and Research Institute, Ahmedabad, Gujarat,
India
Background: Beta-thalassemia major, one of the most prevalent he-
moglobinopathies throughout the world, can be cured by allogeneic
stem cell transplantation. Many patients, however, lack a suitably
matched related sibling donor. Unrelated umbilical cord blood
can be used as an alternative stem cell source for these patients.
This report describes transplantation of 7 children with beta-thalas-
semia major using partially HLA-matched unrelated umbilical cord
blood.
Methods:Conditioning included busulfan 16 mg/kg (day -10 to -7),
cyclophosphamide 200 mg/kg(day -5 to -2), fludarabine 90 mg/kg
